Clinical trial · Observational
Breast Cancer Associated Antibodies
Study of Breast Cancer Associated Antibodies
NCT00331942CI-TRIAL-00000631unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the ability of the Cimmunology process to lead to in vitro antibody production, the ability of the ELISA assays to detect any of those antibodies, and to establish the relationship between the ELISA results and the clinical / pathological status of the patient. The statistical significance of the CAAb test results will be determined.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria BC: * Subjects 18 years or over. * Patients diagnosed with suspected breast cancer, (positive mammography or ultrasound or physical examination) and have a positive biopsy. * Patients willing to participate as evidenced by signing the written informed consent. Exclusion Criteria BC: * Subjects less than 18 years * Patients with prior history of other tumors (except skin cancer) * Hematologic systemic disorders * Patients that have undergone chemotherapy * Patients that have been under anesthesia in the last three months. * Patient not willing to sign written informed consent. Inclusion Criteria Control - * Subjects 18 years or over * Patients willing to participate as evidenced by signing the written informed consent * Subjects had a negative mammography in the past three months. Exclusion Criteria Control - * Subjects less than 18 years * Hematological malignancies * History of any past tumors * Other breast pathology * Patients that have been under anesthesia in the last three months * Patients treated with immuno-suppressant drugs * Patient not willing to sign written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.